Erck becomes CEO in Novavax turnover; Aoxing gets Macfarlan Smith process tech;

> At VLP vaccine developer Novavax, Stanley Erck has been named president and CEO, replacing Rahul Singhvi; James Young becomes chairman. Novavax release

> In the joint venture between Aoxing Pharma and Macfarlan Smith, the latter has transferred its process technology to the former for use in producing API naloxone hydrochloride. Announcement

> Axios Mobile Assets Corp. announced it has achieved FDA compliance for its proprietary trackable pallet and software technology. Axios release

> Logistics service provider Panalpina has announced the accreditation of 20 cool chain locations--10 in Asia--boosting its Qualified Envirotainer Provider status to 43 locations in 27 countries. Item

> Ireland's Corden Pharmachem and two of its executives return to court in the case of a 2008 explosion that killed one worker and seriously injured another. Story

> Bedford Laboratories is now manufacturing topotecan hydrochloride for injection, 4 mg (base)/vial, a bioequivalent to GSK's Hycamtin. Bedford release

> Adeona Pharmaceuticals has agreed to offer commercial-scale manufacturing capabilities for reaZin to Florida-based pharmaceutical preparation manufacturing company TG United. Story

> Indian drugmaker Strides Arcolab has received FDA approval for its new sterile injectables facility in Bangalore, used in the production of lyophilized liquid and dry powder injectables. Item

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.